Study analysis · Frontiers in Oncology · 2023
Cancer cells can consume 10–100 times more glutamine than other amino acids—a relative lab difference—yet drugs that block glutamine keep disappointing. Here's why scientists are rethinking the target.
Some cancers are 'addicted' to glutamine, a nutrient in blood, but blocking glutamine alone hasn't worked well in clinical trials; combining it with other treatments is a promising but unproven idea.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This is like a book report summarizing what many scientists have found about glutamine and cancer. It can give us ideas about how cancer cells use glutamine, but it doesn't prove that changing glutamine will definitely treat cancer in people.
What’s the bottom line?
Some cancer cells need a lot of glutamine to grow. This review explains how cancers use glutamine, how certain genes make them addicted to it, and why blocking glutamine might help treat cancer—especially if combined with other treatments.
How strong is this study?
The authors read a lot of studies and put together a big picture, but they didn't follow a strict recipe to find every study or check how good each one was. So it's a good starting point for ideas, but we need stronger studies to know if the ideas actually work.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
This design cannot establish causation — the findings describe an association, not a cause. Narrative review synthesizes literature without systematic methodology or primary data. It cannot establish cause-effect relationships; it can only describe mechanisms, summarize reported associations, and generate hypotheses.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding statement was provided in the text, so the presence of conflicts cannot be determined.
The provided text is a review article excerpt without a conflict of interest or funding declaration. No author affiliations or industry ties are disclosed. Therefore, bias and funding cannot be assessed from this text.
Key takeaways
- 01
Cancer cells can consume 10–100 times more glutamine than other amino acids (relative consumption, not a risk increase).
- 02
PIK3CA mutations occur in about 30% of breast cancers, 20–30% of colorectal cancers, and 2–7% of non-small cell lung cancers.
- 03
Clinical trials of glutamine metabolism inhibitors so far have had unsatisfactory outcomes.
- 04
Absolute risk or survival benefit was not reported in this study.
- 05
This review does not provide absolute risks such as extra cases per 1,000 people or survival differences.
- 06
The 10–100-fold figure is a lab-based relative measurement of glutamine consumption, not a patient-level risk.
- 07
Any clinical benefit of targeting glutamine metabolism remains unproven, and the absolute risk/benefit was not reported in this study.
Surprising findings
- The glutaminase II pathway has been substantially overlooked in cancer metabolism, yet genetic suppression of GTK completely inhibits pancreatic tumorigenesis in vivo in preclinical models.Most glutamine-cancer research focuses on glutaminase I (GLS). A second pathway with strong preclinical effects challenges the dominant dogma.
- Glutamine is needed by both cancer cells and activated T cells; deleting GLS in cancer cells raises interstitial glutamine and enhances T cell activation in preclinical models.It contradicts the simple idea that less glutamine is always better. Systemic glutamine depletion could harm antitumor immunity, while tumor-specific inhibition might help it.
- Despite strong preclinical rationale, clinical trial outcomes of glutamine metabolism inhibitors remain unsatisfactory.Many mechanism-based cancer therapies look promising in lab models but fail in humans. This review openly acknowledges that gap.
- PIK3CA mutations occur in about 30% of breast cancers, 20–30% of colorectal cancers, and 2–7% of non-small cell lung cancers—common absolute prevalence figures.A metabolic vulnerability tied to glutamine is linked to some of the most common cancer mutations, not a rare subtype.
Practical takeaways
Do not self-prescribe glutamine supplements or restrictive diets to treat cancer based on this review.
This is a narrative review with largely preclinical evidence. No clinical dietary intervention data or absolute benefit was reported.
low confidencePatients with cancer can ask their oncologist whether tumor genomic testing for PIK3CA, KRAS, BRAF, or MYC is relevant and whether any glutamine-metabolism clinical trials are recruiting.
Testing does not guarantee benefit. Most glutamine inhibitor trials are early-phase, and outcomes have been unsatisfactory so far.
low confidenceResearchers and clinicians should consider tumor-specific targeting and combination strategies rather than systemic glutamine depletion alone.
No large randomized trial has proven that this improves survival or quality of life; absolute survival benefits were not reported in this review.
low confidenceContent creators should describe the 10–100-fold glutamine figure as a relative consumption difference in lab studies, not a 10–100-fold increase in cancer risk.
The review does not provide absolute risk or survival numbers, so any patient-level risk framing would be inaccurate.
high confidenceWhy this study matters
Glutamine addiction: a relative 10–100-fold appetite
This narrative review states that cancer cells can consume 10–100-fold more glutamine than other amino acids in relative terms, a phenomenon first observed in 1955. That is a lab-based relative consumption difference, not an absolute risk or survival difference; absolute risks were not reported.
It explains why glutamine is such a hot target in cancer metabolism—and why simple 'cut glutamine' claims are misleading.
Oncogenes flip the glutamine switch
KRAS mutations upregulate glutamine transporters ASCT2, LAT1, and SNAT2; MYC activation drives glutamine addiction in multiple cancer cell lines; PIK3CA mutations upregulate GPT2 via the PDK1-RSK2-ATF4 axis. PIK3CA mutations occur in about 30% of breast cancers, 20–30% of colorectal cancers, and 2–7% of non-small cell lung cancers—absolute prevalence figures.
It suggests a tumor's DNA could reveal a metabolic weakness that drugs might exploit.
The overlooked glutaminase II pathway
The review highlights the glutaminase II pathway, involving GTK/GTL and ω-amidase, which converts glutamine to α-ketoglutaramate and then α-KG without net oxidation. It has been found in human pancreatic and prostate cancers; in pancreatic cancer models, genetic suppression of GTK completely inhibits tumorigenesis in vivo—preclinical animal evidence.
Most cancer-glutamine research focuses on glutaminase I. This overlooked pathway could be a new drug target, especially in hypoxic tumors.
Clinical reality check: single-agent failures
The GLS inhibitor CB-839 has entered phase I and II trials as monotherapy and in combinations, but the review says clinical trial outcomes of glutamine metabolism inhibitors remain unsatisfactory, likely due to metabolic plasticity. No absolute survival benefit was reported.
It's a sobering counterpoint to hype around metabolic cancer therapies.
Glutamine steal: cancer vs immune cells
Cancer cells can outcompete T cells for glutamine in the tumor microenvironment. Deleting GLS in cancer cells increases interstitial glutamine to near-physiological plasma levels and enhances T lymphocyte activation and effector capacity in preclinical studies. The glutamine-mimetic JHU083 restored antitumor immunity in animal studies.
It flips the idea that glutamine is only bad: immune cells need it too, so targeting tumor glutamine specifically might boost immunotherapy.
Combination therapy hypothesis
Because single-agent glutamine inhibition has limited success, the review hypothesizes that combining glutamine metabolism inhibitors with chemotherapy, immunotherapy, or targeted agents may work better. In PIK3CA-mutant colorectal cancer cells, CB-839 plus 5-fluorouracil significantly induced apoptosis versus either alone in preclinical work; a phase I trial (NCT02861300) reported better outcomes for patients with mutated PIK3CA, but absolute benefit was not reported.
It points toward precision cocktails rather than one-size-fits-all metabolic drugs.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some cancer cells need a lot of glutamine to grow. This review explains how cancers use glutamine, how certain genes make them addicted to it, and why blocking glutamine might help treat cancer—especially if combined with other treatments.
Research results
Cancer cells can consume 10–100 times more glutamine than other amino acids (relative consumption, not a risk increase). PIK3CA mutations occur in about 30% of breast cancers, 20–30% of colorectal cancers, and 2–7% of non-small cell lung cancers. Clinical trials of glutamine metabolism inhibitors so far have had unsatisfactory outcomes. Absolute risk or survival benefit was not reported in this study.
What this means - more context
This review does not provide absolute risks such as extra cases per 1,000 people or survival differences. The 10–100-fold figure is a lab-based relative measurement of glutamine consumption, not a patient-level risk. Any clinical benefit of targeting glutamine metabolism remains unproven, and the absolute risk/benefit was not reported in this study.
This 2023 narrative review summarizes glutamine uptake, transport, and metabolism in cancer; oncogene-driven glutamine addiction; the overlooked glutaminase II pathway; and therapeutic strategies targeting glutamine metabolism. Not retracted; no corrections reported.
Glutamine is a major metabolic substrate for many cancers, and cancer cells can consume 10–100-fold more glutamine than other amino acids (a relative consumption difference, not an absolute risk). Oncogenes such as KRAS, BRAF, MYC, and PIK3CA can increase glutamine dependence. Inhibiting glutamine metabolism alone has had limited clinical success, likely due to metabolic plasticity; combination therapies are hypothesized to work better, but clinical validation is pending. Absolute risk or survival benefits were not reported in this review.
Methods Used
Narrative review without systematic search strategy, PRISMA guidelines, inclusion/exclusion criteria, risk-of-bias assessment, or meta-analysis. Synthesizes preclinical and clinical literature on glutamine transporters, metabolic enzymes, oncogene regulation, glutaminase inhibitors, and combination trials.
Main Finding
Dysregulated glutamine metabolism and oncogene-driven glutamine addiction are notable features of many cancers. Cancer cells can consume 10–100-fold more glutamine than other amino acids in relative terms. Single-agent glutamine pathway inhibition has limited clinical success; combining glutamine metabolism inhibitors with chemotherapy, immunotherapy, or targeted agents is hypothesized to improve outcomes. Absolute clinical benefit and absolute risk were not reported.
Confidence Level
Low for clinical efficacy claims because this is a narrative review with no systematic methodology, and most evidence is preclinical. Mechanistic plausibility is high, but clinical trial outcomes of glutamine metabolism inhibitors remain unsatisfactory.
Study Flags
Red Flags
- •Narrative review without systematic search or risk-of-bias assessment
- •Evidence largely preclinical; clinical trial outcomes unsatisfactory
- •No absolute risk/benefit data reported; quantitative claims are relative (e.g., 10–100-fold glutamine consumption)
Surprising Findings
The glutaminase II pathway has been substantially overlooked in cancer metabolism, yet genetic suppression of GTK completely inhibits pancreatic tumorigenesis in vivo in preclinical models.
Most glutamine-cancer research focuses on glutaminase I (GLS). A second pathway with strong preclinical effects challenges the dominant dogma.
Practical Takeaways
Do not self-prescribe glutamine supplements or restrictive diets to treat cancer based on this review.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This is like a book report summarizing what many scientists have found about glutamine and cancer. It can give us ideas about how cancer cells use glutamine, but it doesn't prove that changing glutamine will definitely treat cancer in people.
Strengths
- Comprehensive overview of glutamine metabolism and its role in cancer
- Integrates multiple oncogene pathways (BRAF, KRAS, MYC, mTORC1, PIK3CA)
- Highlights understudied glutaminase II pathway
Weaknesses
- Narrative review, not systematic
- No explicit search strategy or inclusion criteria
- No risk of bias assessment of included studies
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some cancer cells need a lot of glutamine to grow. This review explains how cancers use glutamine, how certain genes make them addicted to it, and why blocking glutamine might help treat cancer—especially if combined with other treatments.
Research results
Cancer cells can consume 10–100 times more glutamine than other amino acids (relative consumption, not a risk increase). PIK3CA mutations occur in about 30% of breast cancers, 20–30% of colorectal cancers, and 2–7% of non-small cell lung cancers. Clinical trials of glutamine metabolism inhibitors so far have had unsatisfactory outcomes. Absolute risk or survival benefit was not reported in this study.
What this means - more context
This review does not provide absolute risks such as extra cases per 1,000 people or survival differences. The 10–100-fold figure is a lab-based relative measurement of glutamine consumption, not a patient-level risk. Any clinical benefit of targeting glutamine metabolism remains unproven, and the absolute risk/benefit was not reported in this study.
This 2023 narrative review summarizes glutamine uptake, transport, and metabolism in cancer; oncogene-driven glutamine addiction; the overlooked glutaminase II pathway; and therapeutic strategies targeting glutamine metabolism. Not retracted; no corrections reported.
Glutamine is a major metabolic substrate for many cancers, and cancer cells can consume 10–100-fold more glutamine than other amino acids (a relative consumption difference, not an absolute risk). Oncogenes such as KRAS, BRAF, MYC, and PIK3CA can increase glutamine dependence. Inhibiting glutamine metabolism alone has had limited clinical success, likely due to metabolic plasticity; combination therapies are hypothesized to work better, but clinical validation is pending. Absolute risk or survival benefits were not reported in this review.
Methods Used
Narrative review without systematic search strategy, PRISMA guidelines, inclusion/exclusion criteria, risk-of-bias assessment, or meta-analysis. Synthesizes preclinical and clinical literature on glutamine transporters, metabolic enzymes, oncogene regulation, glutaminase inhibitors, and combination trials.
Main Finding
Dysregulated glutamine metabolism and oncogene-driven glutamine addiction are notable features of many cancers. Cancer cells can consume 10–100-fold more glutamine than other amino acids in relative terms. Single-agent glutamine pathway inhibition has limited clinical success; combining glutamine metabolism inhibitors with chemotherapy, immunotherapy, or targeted agents is hypothesized to improve outcomes. Absolute clinical benefit and absolute risk were not reported.
Confidence Level
Low for clinical efficacy claims because this is a narrative review with no systematic methodology, and most evidence is preclinical. Mechanistic plausibility is high, but clinical trial outcomes of glutamine metabolism inhibitors remain unsatisfactory.
Study Flags
Red Flags
- •Narrative review without systematic search or risk-of-bias assessment
- •Evidence largely preclinical; clinical trial outcomes unsatisfactory
- •No absolute risk/benefit data reported; quantitative claims are relative (e.g., 10–100-fold glutamine consumption)
Surprising Findings
The glutaminase II pathway has been substantially overlooked in cancer metabolism, yet genetic suppression of GTK completely inhibits pancreatic tumorigenesis in vivo in preclinical models.
Most glutamine-cancer research focuses on glutaminase I (GLS). A second pathway with strong preclinical effects challenges the dominant dogma.
Practical Takeaways
Do not self-prescribe glutamine supplements or restrictive diets to treat cancer based on this review.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This is like a book report summarizing what many scientists have found about glutamine and cancer. It can give us ideas about how cancer cells use glutamine, but it doesn't prove that changing glutamine will definitely treat cancer in people.
Strengths
- Comprehensive overview of glutamine metabolism and its role in cancer
- Integrates multiple oncogene pathways (BRAF, KRAS, MYC, mTORC1, PIK3CA)
- Highlights understudied glutaminase II pathway
Weaknesses
- Narrative review, not systematic
- No explicit search strategy or inclusion criteria
- No risk of bias assessment of included studies
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The authors read a lot of studies and put together a big picture, but they didn't follow a strict recipe to find every study or check how good each one was. So it's a good starting point for ideas, but we need stronger studies to know if the ideas actually work.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
This design cannot establish causation — the findings describe an association, not a cause. Narrative review synthesizes literature without systematic methodology or primary data. It cannot establish cause-effect relationships; it can only describe mechanisms, summarize reported associations, and generate hypotheses.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding statement was provided in the text, so the presence of conflicts cannot be determined.
The provided text is a review article excerpt without a conflict of interest or funding declaration. No author affiliations or industry ties are disclosed. Therefore, bias and funding cannot be assessed from this text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Gut Feelings cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
8 researchersIf this is your work, this is how we attribute it on Fit Body Science. Rui Ni is listed as the lead author.